Preparation and evaluation of bombesin peptide derivatives as potential tumor imaging agents: Effects of structure and composition of amino acid sequence on in vitro and in vivo characteristics

Nuclear Medicine and Biology

Volumn 39, Issue 6, 2012, Pages 795-804

  Okarvi, Subhani M ^a   Jammaz, Ibrahim A ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Biodistribution; Bombesin; Cell binding; Radiolabeling; Technetium 99m

Indexed keywords

ASPARTIC ACID; BOMBESIN DERIVATIVE TC 99M; BOMBESIN RECEPTOR; MERTIATIDE TC 99M; PHENYLALANINE; RADIOISOTOPE; S BENZOYLMERCAPTOACETIC ACID; TECHNETIUM 99M; THIOGLYCOLIC ACID; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID COMPOSITION; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BREAST CANCER; CANCER CELL; CELL ASSAY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MUSCLE LEVEL; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOACTIVITY; SOLID PHASE SYNTHESIS; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; BOMBESIN; CELL LINE, TUMOR; CYSTEINE; DIAGNOSTIC IMAGING; FEMALE; HUMANS; MICE; NEOPLASMS; ORGANOTECHNETIUM COMPOUNDS; PROTEIN TRANSPORT; RECEPTORS, BOMBESIN;

EID: 84864018133     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.01.002     Document Type: Article

References (35)

1. Okarvi S.M. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer. Cancer Treat Rev 2008, 34:13-26.
2. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003, 24:389-427.
3. Zhang H., Chen J., Waldherr C., Hinni K., Waser B., Reubi J.C., et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides with indium-111, leutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 2004, 64:6707-6715.
4. Kroog G.S., Jensen R.T., Battey J.F. Mammalian bombesin receptors. Med Res Rev 1995, 15:389-417.
5. 13]bombesin distinct from the receptor for gastrin-releasing peptide: identification of a fourth bombesin receptor subtype (BB4). Proc Natl Acad Sci U S A 1995, 92:6205-6209.
6. Fleischmann A., Waser B., Gebbers J.-O., Reubi J.C. Gastrin-releasing peptide receptors in normal and neoplastic human uterus: involvement of multiple tissue compartments. J Clin Endocrinol Metab 2005, 90:4722-4729.
7. Okarvi S.M. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev 2004, 24:357-397.
8. 111In-labeled DTPA- or DOTA-bombesin analogs for receptor targeted scintigraphy and radionuclide therapy. J Nucl Med 2002, 43:1650-1656.
9. 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties. Bioconjugate Chem 2007, 18:1110-1117.
10. Faintuch B.L., Teodoro R., Duatti A., Muramoto E., Faintuch S., Smith C.J. Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies. Nucl Med Biol 2008, 35:401-411.
11. 2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer. J Nucl Med 1997, 38:1221-1229.
12. Pradhan T.K., Katsuno T., Taylor J.E., Kim S.H., Ryan R.R., Mantey S.A., et al. Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes. Eur J Pharmacol 1998, 343:275-287.
13. Mantey S.A., Weber H.C., Sainz E., Akeson M., Ryant R.R., Pradhan T.K., et al. Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors. J Biol Chem 1997, 272:26062-26071.
14. 14]bombesin(6-14). Clin Cancer Res 2002, 8:1139-1146.
15. 99mTc-labelling of bz-MAG3-tricarbonyl-peptides, their radiochemical evaluation and in vitro receptor-binding. J Labelled Compd Radiopharm 2000, 43:1193-1204.
16. Okarvi S.M. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur J Nucl Med 2001, 28:929-938.
17. Grant G.A. Synthetic peptides 2002, Oxford University Press, New York.
18. Okarvi S.M. Synthesis, radiolabeling and in vitro and in vivo characterization of a technetium-99m-labeled alpha-M2 peptide as a tumor imaging agent. J Pept Res 2004, 63:460-468.
19. 3 and biodistribution of by-products. Appl Radiat Isot 1988, 39:121-129.
20. Schroeder R.P.J., Cristina M., Reneman S., Melis M.L., Breeman W.A.P., de Blois E., et al. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging 2010, 37:1386-1396.
21. Fukuoka M., Kiyohara T., Kobayashi T., Kojima A., Tanaka A., Kubodera A. Synthesis and preclinical evaluation of technetium-99m-labeled hippurate analogues. Nucl Med Biol 1995, 22:181-191.
22. Okarvi S.M., Al Jammaz I. Synthesis and evaluation of a technetium-99m labeled cytotoxic bombesin peptide conjugate for targeting bombesin receptor-expressing tumors. Nucl Med Biol 2010, 37:277-288.
23. 11C]DASB for measuring endogenous serotonin with PET: binding studies. Nucl Med Biol 2005, 32:129-136.
24. Zhu W.-Y., Göke B., Williams J.A. Binding, internalization, and processing of bombesin by rat pancreatic acini. Am J Physiol Gastrointest Liver Physiol 1991, 261:G57-G61.
25. Siegrist W., Solca F., Stutz S., Giuffre L., Carrel S., Girard J., et al. Characterization of receptors for α-melanocyte-stimulating hormone on human melanoma cells. Cancer Res 1989, 49:6352-6358.
26. Okarvi S.M., Jammaz I.A. Preparation and in vitro and in vivo evaluation of technetium-99-labeled folate and methotrexate conjugates as tumor imaging agents. Cancer Biother Radiopharm 2006, 21:49-60.
27. Guide for the care and use of laboratory animals 1996, National Academy Press, Washington, D.C.
28. Okarvi S.M., Adriaens P., Verbruggen A. Comparison of the labelling characteristics of mercaptoacetyltriglycine (MAG3) with different S-protective groups. J Labelled Compd Radiopharm 1997, 39:853-874.
29. Giacchetti S., Gauvillé C., De Crémoux P., Bertin L., Berthon P., Abita J.P., et al. Characterization, in some human breast cancer cell lines, of gastrin-releasing peptide-like receptors which are absent in normal breast epithelial cells. Int J Cancer 1990, 46:293-298.
30. 4) bombesin by tumor cells. Prostate 1994, 25:29-38.
31. Heinz-Erian P., Coy D.H., Tamura M., Gardner J.D., Jensen R.T. [D-Phe12]bombesin analogues: a new class of bombesin receptor antagonists. Am J Physiol Gastrointest Liver Physiol 1987, 252:G439-G442.
32. Ginj M., Zhang M.H., Waser B., Cescato R., Wild D., Wang X., et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 2006, 103:16436-16441.
33. Rolleman E.J., Valkema R., de Jong M., Kooij P.P.M., Krenning E.P. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med 2003, 30:9-15.
34. 2: an in vitro/in vivo structure-activity relationship study where ×=0-,3-,5-,8-, and 11-carbon tethering moieties. Bioconjugate Chem 2003, 14:93-102.
35. Jensen R.T., Battey J.F., Spindel E.R., Benya R.V. International union of pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev 2008, 60:1-42.